COMPUTATIONAL STUDIES OF SYNTHETIC AND PLANT-DERIVED COMPOUNDS AGAINST CARDIOVASCULAR DISEASE TARGETS
Abstract
Knowledge of cardiovascular diseases and improved diagnostic capacity is rapidly expanding with the advancement of medical sciences. However, heart diseases are a challenge to human life. Few important therapeutic targets for cardiovascular diseases were collected from mining of various bibliographic sources. Different proteins and bioactive small molecules are taken into consideration for target search. From ancient times, medicinal plants are shown to have remedial effect on cardiovascular system of human body, yet their modes of action are not completely understood till now. Selected plant derivatives, which have been examined under in vitro conditions to be effective against various heart diseases, were subjected to molecular docking with proposed targets using a bioinformatics tool, Hex 8.0. We have explored eight targets for five types of cardiovascular diseases and ten different ligands from herbal plants with a brief description about the cardiovascular diseases, their symptoms, target, ligand, source of the ligand and their mechanism of action. All the reported synthetic and phytocompounds were found to have good binding energies with all potential disease targets. Among all, Forskolin is found to be the best inhibitor of Angiotensin II type I receptor with the E-score of -369.96 for Atherosclerosis.
Keywords:
Molecular docking, cardiovascular, Hex, phytocompoundsDOI
https://doi.org/10.25004/IJPSDR.2016.080303References
2. Lisina KV, Piramanayagam S. An in-silico Study on Thymoma with Inhibitors from Petiole and Tender Coconut Water from Cocos nucifera. Int. J. Pharm. Sci. Drug Res. 2014; 6: 52-59.
3. Baghel MS, Goswami K. Bcl-2 Targeted Structural Based Computer Aided Drug Design (CAAD) For Therapeutic Assessment of Ricin in Prostate Cancer. Int. J. Pharm. Sci. Drug Res. 2015; 7:168-171.
4. Rodbell M. The role of hormone receptors and GTP-regulatory proteins in membrane transduction. Nature. 1980; 284: 17-22.
5. Garret A, Fitz, Gerald MD. Coxibs and Cardiovascular Disease. The New England Journal of Medicine. 2004; 351: 1709-1711.
6. Fu GD, Sun YL, Hamet P, Inagami T. The angiotensin II type 1 receptor and receptor-associated proteins. Cell Research. 2001; 11:165-180.
7. Bilfinger TV, Salzet M, Fimiani C, Deutsch DG, Tramu G, Stefano GB. Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. International Journal of Cardiology 1998; 64 (Suppl 1): S15-S22.
8. Kim van der heiden, Simon C, Le A. luong, MZ, Paul CE. Role of nuclear factor κB in cardiovascular health and disease. Clinical Science. 2010; 118: 593-605.
9. Hillard CJ. Endocannabinoids and vascular function. Journal of Pharmacology and Experimental Therapeutics. 2000; 294:27-32.
10. Randall MD, Harris D, Kendall DA, Ralevic V. Cardiovascular effects of cannabinoids. Pharmacology and Therapeutics. 2002; 95: 191-202.
11. Pacher P, Bátkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Handbook of Experimental Pharmacology. 2005; 168: 599-625.
12. Underdown NJ, Hiley CR, Ford WR. Anandamide reduces infarct size in rat isolated hearts subjected to ischaemiareperfusion by a novel cannabinoid mechanism. Br J Pharmacol. 2005; 146: 809-816.
13. Andrew O. Maree, MSc, MD; Desmond J. Fitzgerald, MD. Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease. Circulation 2007; 115: 2196-2207.
14. Matsoukas MT, Cordomí A, Ríos S, Pardo L, Tselios T. Ligand binding determinants for angiotensin II type 1 receptor from computer simulations. J Chem Inf Model. 2013; 11: 2874-2883.
15. Kleemann R, Verschuren L, Morrison M, Zadelaar S, van Erk MJ, Wielinga PY, Kooistra T. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis. 2011; 1: 44-52.
16. Vázquez-Agell M, Urpi-Sarda M, Sacanella E, Camino-López S, Chiva-Blanch G, Llorente-Cortés V, Tobias E, Roura E, Andres-Lacueva C, Lamuela-Raventós RM, Badimon L, Estruch R. Cocoa consumption reduces NF-κB activation in peripheral blood mononuclear cells in humans. Nutr Metab Cardiovasc Dis. 2013; 3: 257-263.
17. Rivera J, Lozano ML, Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica. 2009; 5: 700-711
18. Denniss AR, Marsh JD, Quigg RJ, Gordon JB, Colucci WS. Beta-adrenergic receptor number and adenylate cyclase function in denervated transplanted and cardiomyopathic human hearts.Circulation.1989; 79: 1028-1034.
19. Hippisley-Cox J. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ.2005; 330-1366.
20. Filippo CD, Rossi F, Rossi S, D’Amico M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. JLB. 2003; 3: 453-459.
Published
Abstract Display: 391 
PDF Downloads: 513 
